Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1111
Abstract: Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate to severe atopic dermatitis (AD). To assess the relationship between abrocitinib plasma concentrations and heart rate (HR)–corrected QT (QTc) and HR and… read more here.
Keywords: effect abrocitinib; healthy volunteers; effect; population pharmacokinetic ... See more keywords
Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long‐Term Storage at Room Temperature
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1129
Abstract: Storage of trametinib tablets outside of 2‐8°C protected from moisture may lead to loss of dimethyl sulfoxide (DMSO) and adversely impact trametinib bioavailability. In this open‐label, phase 1, single‐dose, randomized, 2‐treatment, 2‐period crossover study in… read more here.
Keywords: single dose; healthy volunteers; bioavailability; trametinib ... See more keywords
Pharmacokinetics and Safety Study of HN0037, a Novel Anti‐Human Herpes Simplex Virus Inhibitor, in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1138
Abstract: HN0037 is a helicase‐primase inhibitor developed to treat herpes simplex virus (HSV) infection. This study evaluated the safety, tolerability, and pharmacokinetics of HN0037, following oral administration in healthy volunteers. This double‐blind, placebo‐controlled, phase 1 study… read more here.
Keywords: healthy volunteers; simplex virus; inhibitor; study ... See more keywords
Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1163
Abstract: Brepocitinib is a tyrosine kinase 2 and Janus kinase 1 inhibitor in development for treatment of inflammatory autoimmune diseases. This analysis aimed to add to the pharmacokinetic knowledge of the medication, through development of a… read more here.
Keywords: volunteers patients; healthy volunteers; brepocitinib; model ... See more keywords
Population Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim Biosimilar GP40141 and Reference Product in Healthy Volunteers to Evaluate Biosimilarity
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1367
Abstract: GP40141 is a romiplostim biosimilar. A Phase 1 clinical trial was previously conducted in healthy volunteers to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), and safety of GP40141 compared to the reference romiplostim (NCT05652595). Using noncompartmental… read more here.
Keywords: healthy volunteers; romiplostim; reference; population ... See more keywords
Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1380
Abstract: Osteoarthritis (OA) pain management options are currently limited. Fasinumab, an anti‐nerve growth factor monoclonal antibody, has been investigated in healthy volunteers and patients with OA‐related pain, among other conditions. Data from 12 Phase I‐III clinical… read more here.
Keywords: pharmacokinetics fasinumab; healthy volunteers; volunteers patients; population pharmacokinetics ... See more keywords
Amenamevir: Studies of Potential CYP3A‐Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.586
Abstract: Amenamevir (formerly ASP2151) is a helicase‐primase inhibitor being developed for the treatment of herpesvirus infection. Amenamevir is both a substrate and inducer of cytochrome P450 (CYP) 3A4. Three studies were done in healthy volunteers to… read more here.
Keywords: cyp3a mediated; cyp3a; healthy volunteers; geometric mean ... See more keywords
Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients With Diabetic Foot Ulcers
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.654
Abstract: Daprodustat, a small‐molecule inhibitor of prolyl hydroxylases, prevents breakdown of hypoxia‐inducible factor (HIF), leading to increased transcription of HIF‐responsive genes. This randomized, placebo‐controlled study evaluated the safety, tolerability, and pharmacokinetics of a topical formulation of… read more here.
Keywords: daprodustat; safety tolerability; safety; healthy volunteers ... See more keywords
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.865
Abstract: Venglustat is a small‐molecule glucosylceramide synthase (GCS) inhibitor designed to reduce the production of glucosylceramide (GL‐1) and thus is expected to substantially reduce formation of glucosylceramide‐based glycosphingolipids. Because of its effect on glycosphingolipid formation, GCS… read more here.
Keywords: safety tolerability; safety; healthy volunteers; pharmacokinetics pharmacodynamics ... See more keywords
Detection of erythropoiesis stimulating agent Luspatercept after administration to healthy volunteers for antidoping purposes
Sign Up to like & getrecommendations! Published in 2022 at "Drug Testing and Analysis"
DOI: 10.1002/dta.3341
Abstract: Abstract Luspatercept (Reblozyl®) is a newly approved anti‐anemic drug prohibited by the World Anti‐Doping Agency. It promotes erythropoiesis by limiting apoptosis of immature erythroblasts and the risk of misuse by athletes for doping is high.… read more here.
Keywords: volunteers antidoping; administration; healthy volunteers; erythropoiesis stimulating ... See more keywords
Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2055
Abstract: We characterized the population pharmacokinetics of anifrolumab, a type I interferon receptor–blocking antibody. Pharmacokinetic data were analyzed from the anifrolumab (intravenous [IV], every 4 weeks) arms from 5 clinical trials in patients with systemic lupus… read more here.
Keywords: pharmacokinetics anifrolumab; healthy volunteers; patients systemic; population pharmacokinetics ... See more keywords